

Wellcozyme HIV 1+2 : code VK54/55 / Murex Diagnostics Limited.

Contributors

Murex Diagnostics Limited

Publication/Creation

[between 1990 and 1999?]

Persistent URL

<https://wellcomecollection.org/works/yw8arp2s>

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).

**wellcome
collection**

Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>

Wellcozyme HIV 1+2

CODE
VK54/55

Dilute wash fluid (▶)
(Refer to direction circular).


POSITIVE REACTION

1	Assemble required number of antigen coated strips in the frame.	
2	Add 25µl sample <i>Note: Leave six wells for the control samples, which should be added last.</i>	
3	Add 25µl of negative control to wells C1, D1, E1 and F1.	
4	Add 25µl of each of the positive controls (anti-HIV-1 and anti-HIV-2) to wells G1 and H1 respectively.	
5	Add 25µl sample diluent to each well being used.	
6	Cover wells with lid and incubate under humid conditions at 37°C for 30 minutes.	
7	Reconstitute the conjugate according to the instructions in the direction circular, 15 minutes before use.	
8	Wash the wells. Automated washers - refer to direction circular or Handwash 3x.	
9	Add 50µl conjugate.	
10	Cover wells with lid and incubate under humid conditions at 37°C for 30 minutes.	
11	Reconstitute substrate according to the instructions in the direction circular, 15 minutes before use.	
12	Wash the wells. Automated washers - refer to direction circular or Handwash 3x, allowing to soak not more than 2 minutes then hand wash 3x. <i>Note: Do not allow wells to stand empty after completion of the wash.</i>	
13	Add 50µl substrate	
14	Cover wells with lid and incubate under humid conditions at 37°C for 20 minutes. <i>Note: Avoid direct sunlight</i>	
15	Reconstitute amplifier according to instructions in direction circular 15 minutes before use.	



Microwell surface

HIV-1 Ag (recombinant) and HIV-2 Ag (peptide)

Anti-HIV-1 or Anti-HIV-2



HIV-1 Ag and HIV-2 Ag conjugated to alkaline phosphates



Wellcozyme HIV 1+2

CODE
VK54/55

16 Add 100 μ l amplifier.



17 Incubate at 20° to 25°C for exactly 10 minutes


Note: Avoid direct sunlight

18 Add 50 μ l stop solution



19 Read at 492nm within 15 minutes. On dual beam readers use 690nm as the reference wavelength.

20 For calculation of results, refer to direction circular.



■ Total Confidence

The assay has been designed to simultaneously detect antibodies to both HIV-1 and HIV-2 without comprising sensitivity to HIV-1, thereby ensuring confidence in results. Confidence in results is further reinforced by the provision of positive controls to both HIV-1 and HIV-2 antibodies for verification of satisfactory assay performance.

■ High Sensitivity

The use of cyclic enzyme amplification technology allows the test to detect a lower concentration of antibody in samples than can be achieved with a conventional enzyme immunoassay.

■ Excellent Specificity

The antigen sandwich format which incorporates recombinant HIV-1 and synthetic peptide HIV-2 antigens has produced a highly specific assay. This minimises unnecessary confirmation testing whilst maximising confidence in results.

■ Convenience

The Wellcozyme HIV-1+2 assay enables screening for two viruses in the time usually required to detect one virus, therefore greatly improving user convenience.

■ High Speed

Accurate and reliable results can be achieved in under 2 hours.

Key Applications for Wellcozyme HIV 1+2

Wellcozyme HIV 1+2 is an enzyme immunoassay for the detection of antibody to HIV-1 and HIV-2 in serum or plasma.

Key applications include:

- (1) The screening of donated blood to prevent transmission of either HIV-1 or HIV-2 by transfusion.
- (2) Diagnostic testing for HIV-1 and HIV-2 infection in the clinical laboratory.
- (3) Epidemiological surveys of HIV antibody prevalence.

Kit Contents

Antigen coated microwells
Microwell plate lid(s)
Resealable bag for storage of microwells
Sample diluent
Conjugate and conjugate diluent
Substrate and substrate diluent
Amplifier and amplifier diluent
Wash fluid concentrates A and B
Negative control serum
Anti-HIV-1 positive control serum
Anti-HIV-2 positive control serum

Instrumentation systems and software are available to support the wide range of Murex Diagnostics assays. For further information, please contact your local Murex Diagnostics representative or our main office at the address below.

murex

Murex Diagnostics Limited, Central Road, Temple Hill, Dartford,
Kent DA1 5LR England.

Tel: (0322) 277711 Tlx: Murex G 896113 Fax: (0322) 273288

Ask for Murex Diagnostics sales office or distributor: Australia (02) 8785855 Belgium (053) 839700 Brazil (011) 262 5511 Eire (01) 6267111 Far East Region (Singapore) (065) 5682106/2177 France (1) 46 12 49 12 Germany (05) 139 899444 Italy (06) 911 891 Middle East Region (Dubai) (04) 822835 The Netherlands (030) 412550 New Zealand (09) 276 1877 Portugal (01) 476 2531 Southern and Eastern Africa, Johannesburg (011) 975 1146 Spain (01) 673 7385 United Kingdom and Nordic region (0322) 282568. All other countries: (44) 322 282568 or write to International Sales, Murex Diagnostics Ltd, Central Road, Dartford, Kent, DA1 5LR, England.

Murex is a trademark of International Murex Technologies Corporation (IMTC).